Kestra Medical Q1 FY26 revenue up 52% to $19.4M; raises FY26 guidance to $88M

KESTRA MEDICAL TECHNOLOGIES, LTD.

2025-Q1 EPS reported -$0.50 revenue$19,371,000

Revenue $19.4M (+52% YoY); gross margin expanded to 45.7% from 32.9%.
GAAP net loss $25.8M vs $20.3M; adjusted EBITDA loss $19.4M vs $15.7M.
4,205 prescriptions for ASSURE system, up 51% YoY; driven by new accounts and in-network mix.
FY26 revenue guidance raised to $88M, representing 47% growth over FY25.
Cash and equivalents $201.2M as of July 31, 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.